Thirty Montana healthcare facilities plan to share radiology images and reports using a new cloud-based technology, called eMix (Electronic Medical Information Exchange).
Thirty Montana healthcare facilities plan to share radiology images and reports using a new cloud-based technology, called eMix (Electronic Medical Information Exchange). DR Systems, developer of eMix, will begin implementing the technology in late November. The cloud computing approach embodied in eMix, which utilizes computers connected through the Internet, requires no capital outlay for hardware or software. The eMix system will be fully operational in early 2010a cross all 30 facilities, which have banded together to form the Image Movement of Montana. This grassroots organization was formed to counter image-sharing problems among rural healthcare providers in Montana. Having the means to transfer patient studies long distances is particularly important for rural facilities, because they sometimes must transport patients to urban hospitals for treatment. The standard workaround approaches – burning and mailing CDs, printing film, or faxing reports – are labor-intensive, costly, and too slow for emergency situations.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.